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Significance of this study
What is already known about this subject?
 ► Sodium- glucose cotransporter-2 inhibitors (SGLT2i),
the newest class of antihyperglycemic medications,
have been linked to an increased occurrence of
Fournier’s gangrene, a rare, necrotizing fasciitis of
the perineum, using data from the Food and Drug
Administration (FDA) Adverse Event Reporting
System, and an FDA warning was issued in response 
to this finding.
What are the new findings?
 ► Using administrative data from the commercially
insured US population and an active- comparator,
new- user cohort study design, we found no differ-
ence in risk of Fournier’s gangrene between patients 
initiating SGLT2i and patients initiating dipeptidyl
peptidase-4 inhibitors, a similar branded second- 
line antihyperglycemic medication class.
How might these results change the focus of 
research or clinical practice?
 ► This study suggests that patients who are pre-
scribed SGLT2i in real- world practice may not be
at increased risk for Fournier’s gangrene compared
with patients who are prescribed similar second- 
line, branded antihyperglycemic medications.
 ► Given the very low incidence of Fournier’s gangrene
in the USA, this evidence must be weighed against
the clinical benefits of SGLT2i in patients with type 2
diabetes mellitus.
ABSTRACT
Background Sodium- glucose cotransporter-2 inhibitors 
(SGLT2i) have been associated with increased occurrence 
of Fournier’s gangrene (FG), a rare but serious form of 
necrotizing fasciitis, leading to a warning from the Food 
and Drug Administration. Real- world evidence on FG is 
needed to validate this warning.
Methods We used data from IBM MarketScan 
(2013–2017) to compare the incidence of FG among 
adult patients who initiated either SGLT2i, a dipeptidyl 
peptidase-4 inhibitor (DPP4i), or any non- SGLT2i 
antihyperglycemic medication. FG was defined using 
inpatient International Classification of Diseases, Ninth 
Edition and Tenth Edition diagnosis codes 608.83 and 
N49.3, respectively, combined with procedure codes 
for debridement, surgery, or systemic antibiotics. We 
estimated crude incidence rates (IRs) using Poisson 
regression, and crude and adjusted HRs (aHR) and 
95% CIs using standardized mortality ratio- weighted 
Cox proportional hazards models. Sensitivity analyses 
examined the impact of alternative outcome definitions.
Results We identified 211 671 initiators of SGLT2i 
(n=93 197) and DPP4i (n=118 474), and 305 329 initiators 
of SGLT2i (n=32 868) and non- SGLT2i (n=272 461). Crude 
FG IR ranged from 3.2 to 3.8 cases per 100 000 person- 
years during a median follow- up of 0.51–0.58 years. 
Compared with DPP4i, SGLT2i initiation was not associated 
with increased risk of FG for any outcome definition, with 
aHR estimates ranging from 0.25 (0.04–1.74) to 1.14 
(0.86–1.51). In the non- SGLT2i comparison, we observed 
an increased risk of FG for SGLT2i initiators when using FG 
diagnosis codes alone, using all diagnosis settings (aHR 
1.80; 0.53–6.11) and inpatient diagnoses only (aHR 4.58; 
0.99–21.21).
Conclusions No evidence of increased risk of FG 
associated with SGLT2i was observed compared with 
DPP4i, arguably the most relevant clinical comparison. 
However, uncertainty remains based on potentially higher 
risk in the broader comparison with all non- SGLT2i 
antihyperglycemic agents and the rarity of FG.
Trial registration number EUPAS Register Number 
30018.
InTRoduCTIon
In August 2018, the US Food and Drug 
Administration (FDA) released a safety 
warning linking sodium- glucose cotrans-
porter-2 inhibitors (SGLT2i), the newest 
class of antihyperglycemic medications, to an 
increased occurrence of Fournier’s gangrene 
(FG), a rare, necrotizing fasciitis of the 
perineum.1 Despite overall low incidence in 
the USA (1.6 cases per 100 000 male patients),2 
FG is often accompanied by poor manage-
ment options and prognosis3 and results in 
debilitating complications and disfigurement 
in most infected patients. Approximately 
7.5% of patients with FG die.2 4–6
The FDA warning, which attracted media 
attention,7 was based on 12 FG cases (7 men, 
5 women) reported through the FDA Adverse 
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Event Reporting System (FAERS) from 2013 to 2018, as 
well as individual case reports in the medical literature.8–10 
A more recent review of the FAERS and case reports 
yielded similar conclusions based on 55 FG cases among 
patients receiving SGLT2i from 2013 to 2019, compared 
with 19 FG cases among patients receiving other antihy-
perglycemic medications from 1984 to 2019.11 However, 
the structure and quality of FAERS reporting precluded 
any ability to estimate comparative incidence or establish 
causality.12
To address these limitations and to validate evidence 
behind the FDA warning in a real- world setting, we eval-
uated the association between SGLT2i initiation and FG 
risk in a large healthcare administrative claims database 
from the commercially insured US population, using an 
active- comparator, new- user (ACNU) study design.13
MeTHods
data source
We used data from IBM MarketScan from 1 January 2012 
to 31 December 2017. The base population consisted 
of all patients with ≥1 prescription dispensing claim for 
an SGLT2i or dipeptidyl peptidase-4 inhibitor (DPP4i) 
between 1 April 2013 (US market entry date of canagli-
flozin14) and 30 June 2017 (to allow at least 6 months of 
follow- up), identified using national drug codes (NDCs). 
Eligible patients were adults aged 18–64 years with ≥12 
months of continuous enrollment in MarketScan prior 
to first eligible prescription dispensing claim without a 
prescription for either SGLT2i or DPP4i (washout period 
to define new use). The study protocol was registered 
with the European Network of Centres for Pharmaco-
epidemiology and Pharmacovigilance on 5 June 2019 
(http://www. encepp. eu/ encepp/ viewResource. htm? id= 
30019).
exposure definitions
Exposure to a study drug was defined by ≥2 same- drug 
class prescription dispensing claims of either an SGLT2i 
or DPP4i within a predefined ‘prescription window’ (first 
prescription’s recorded days’ supply plus a 30- day grace 
period). The second prescription served as the index 
date for the analysis. This two- prescription approach 
restricts the analysis to a cohort for whom we are more 
confident were taking the cohort drugs, compared with 
cohorts requiring just a single prescription. We excluded 
patients who received a comparator drug (including the 
empagliflozin- linagliptin combination drug) prior to or 
on the index date.
outcome definitions
Fournier’s gangrene was defined using the International 
Classification of Diseases, Ninth Edition and Tenth 
Edition (ICD-9 and ICD-10) diagnosis codes 608.83 
(‘vascular disorders, including Fournier’s disease’) and 
N49.3 (‘Fournier’s gangrene’), respectively. Patients who 
received an FG diagnosis code in the 12 months prior to 
the index date were excluded from analysis. To increase 
outcome specificity, we required FG diagnoses to either 
occur in an inpatient setting or be followed by a hospital-
ization within 7 days, and be additionally accompanied 
by systemic antibiotic, debridement, or related surgical 
procedure4 within 7 days (primary outcome definition). 
Codes were informed through prior literature15–25 and 
clinical guidance.
Acknowledging the lack of standard, validated claims- 
based definitions for FG, and to examine the possible 
impact of outcome misclassification in a rare outcome 
setting, we considered less stringent (higher sensitivity, 
reduced specificity) secondary outcome definitions. 
First, we removed the systemic antibiotic requirement 
(as NDCs may not be billed during inpatient stays) and 
considered only debridement and surgical procedures. 
Second, we applied various diagnosis- only definitions, 
which have typically been used in published literature.2 4 5
We further identified and evaluated additional ICD-9 
and ICD-10 diagnosis codes with a forward- backward 
mapping approach using the General Equivalence 
Mappings crosswalk provided by the Centers for Medi-
care and Medicaid Services.26 Finally, because there are 
no specific codes for FG in women, we used a combina-
tion of codes (785.4, 616.3, 616.4, N75.1, N76.4, I96) 
used in previous epidemiologic study of FG.2 4 5
statistical analysis
Follow- up for outcomes started at the index date (date 
of the second prescription) and was censored at the first 
occurrence of either FG, treatment discontinuation, a 
prescription of the comparator drug class (all cohorts), 
disenrollment, or 31 December 2017.
We estimated propensity scores using multivariable 
logistic regression to control for measured confounding, 
with baseline covariates (patient demographics, comor-
bidities, risk factors for FG,5 6 9 10 12 medication use history, 
and baseline healthcare utilization) measured in the 12 
months prior to index date. All propensity score anal-
yses were performed separately for patients with index 
dates before versus after 1 October 2015, to account for 
possible billing changes in the ICD-9 versus ICD-10 eras. 
Covariate balance was assessed using standardized mean 
differences.27
We estimated the average treatment effect in the 
treated by standardizing the distribution of measured 
covariates to the SGLT2i cohorts using standardized 
mortality ratio (SMR) weighting.28 We estimated crude 
incidence rates (IRs) using Poisson regression, and 
crude and adjusted HRs (aHR) and 95% CIs using SMR- 
weighted Cox proportional hazards models. All analyses 
were performed using SAS V.9.4.
sensitivity analyses
To reflect the comparison made in the FAERS analysis, 
we broadened the comparator group to include all non- 
SGLT2i antihyperglycemic medications (sulfonylureas, 
thiazolidinediones, DPP4i, glucagon- like peptide-1 
receptor agonists, and insulins). In this analysis, we 
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Table 1 Key baseline characteristics of eligible initiators of SGLT2i, compared with initiators of DPP4i and non- SGLT2i 
antihyperglycemic medications, before and after implementation of SMR weighting* (365- day washout period)
Characteristics
(measured 1 year (365 
days) prior to date of 
cohort drug initiation)


















Age, mean (SD) 52.2 (8.3) 52.9 (8.2) 52.2 (8.3) 51.3 (8.6) 49.8 (10.3) 51.3 (8.6)
Male 50 018 (53.7) 66 025 (55.7) 48 811 (51.7) 16 870 (51.3) 135 938 (49.9) 16 945 (51.4)
Diabetes comorbidities
 Nephropathy 4422 (4.7) 5298 (4.5) 4485 (4.8) 748 (2.3) 8052 (3.0) 748 (2.3)
 Neuropathy 9197 (9.9) 8156 (6.9) 9460 (10.0) 1604 (4.9) 13 028 (4.8) 1609 (4.9)
 Retinopathy 6895 (7.4) 6265 (5.3) 6724 (7.1) 1186 (3.6) 9274 (3.4) 1185 (3.6)
 Peripheral vascular 
disease
1387 (1.5) 1978 (1.7) 1412 (1.5) 359 (1.1) 3452 (1.3) 361 (1.1)
General health comorbidities
 Obesity 25 256 (27.1) 24 921 (21.0) 26 087 (27.7) 8411 (25.6) 60 653 (22.3) 8461 (25.7)
 Alcohol abuse 693 (0.7) 1075 (0.9) 701 (0.7) 254 (0.8) 3526 (1.3) 255 (0.8)
 COPD 10 374 (11.1) 13 484 (11.4) 10 791 (11.4) 3795 (11.5) 31 138 (11.4) 3812 (11.6)
 Liver disease 633 (0.7) 897 (0.8) 655 (0.7) 165 (0.5) 2328 (0.9) 165 (0.5)
 Renal disease 3218 (3.5) 6824 (5.8) 3381 (3.6) 650 (2.0) 12 481 (4.6) 646 (2.0)
 Chronic kidney disease 2642 (2.8) 5991 (5.1) 2787 (3.0) 553 (1.7) 10 874 (4.0) 550 (1.7)
 History of cancer 4217 (4.5) 6316 (5.3) 4302 (4.6) 1422 (4.3) 13 479 (4.9) 1421 (4.3)
 Hypertension 66 737 (71.6) 81 683 (68.9) 67 919 (72.0) 21 880 (66.6) 164 202 (60.3) 21 966 (66.7)
 Congestive heart failure 2383 (2.6) 3889 (3.3) 2381 (2.5) 604 (1.8) 8546 (3.1) 603 (1.8)
 Acute myocardial 
infarction
1572 (1.7) 2343 (2.0) 1551 (1.6) 410 (1.2) 5296 (1.9) 412 (1.2)
 Cerebrovascular disease 3226 (3.5) 4747 (4.0) 3181 (3.4) 899 (2.7) 9959 (3.7) 894 (2.7)
 Depression 9996 (10.7) 11 560 (9.8) 10 569 (11.2) 3432 (10.4) 28 693 (10.5) 3453 (10.5)
 Smoking 4739 (5.1) 6739 (5.7) 4845 (5.1) 1619 (4.9) 17 018 (6.2) 1623 (4.9)
 Dyslipidemia 67 685 (72.6) 79 944 (67.5) 68 433 (72.6) 21 698 (66.0) 148 508 (54.5) 21 817 (66.2)
 Ischemic heart disease 9358 (10.0) 11 794 (10.0) 9364 (9.9) 2533 (7.7) 22 318 (8.2) 2543 (7.7)
Prior medication use
 Statins 58 728 (63.0) 71 108 (60.0) 58 907 (62.5) 17 497 (53.2) 124 490 (45.7) 17 593 (53.4)
 ACEI 41 685 (44.7) 52 489 (44.3) 42 320 (44.9) 12 321 (37.5) 98 889 (36.3) 12 367 (37.5)
 Angiotensin receptor 
blockers
25 726 (27.6) 30 146 (25.4) 26 040 (27.6) 8275 (25.2) 52 913 (19.4) 8332 (25.3)
 Beta blockers 27 084 (29.1) 34 111 (28.8) 27 583 (29.2) 8697 (26.5) 78 305 (28.7) 8679 (26.3)
 Calcium channel 
blockers
18 391 (19.7) 24 437 (20.6) 18 564 (19.7) 5869 (17.9) 48 854 (17.9) 5876 (17.8)
 Loop diuretics 6203 (6.7) 7763 (6.6) 6584 (7.0) 1645 (5.0) 15 660 (5.7) 1643 (5.0)
 Non- loop diuretics 31 322 (33.6) 38 517 (32.5) 32 105 (34.0) 10 608 (32.3) 77 330 (28.4) 10 650 (32.3)
 Aspirin 5146 (5.5) 5691 (4.8) 5412 (5.7) 1092 (3.3) 11 438 (4.2) 1089 (3.3)
 Glucocorticoids 16 867 (18.1) 21 037 (17.8) 17 186 (18.2) 6664 (20.3) 51 214 (18.8) 6690 (20.3)
 Metformin 74 749 (80.2) 101 535 (85.7) 74 988 (79.5) 25 985 (79.1) 185 703 (68.2) 26 133 (79.3)
 Sulfonylureas 30 026 (32.2) 40 174 (33.9) 30 929 (32.8) – – –
 GLP-1 receptor agonist 23 321 (25.0) 6122 (5.2) 24 966 (26.5) – – –
 Thiazolidinediones 7717 (8.3) 8059 (6.8) 8278 (8.8) – – –
 Insulin (long- acting) 26 276 (28.2) 14 893 (12.6) 27 593 (29.3) – – –
Measures of healthcare utilization in the year prior to index date
Number of HbA1c tests in the past year
 0 7355 (7.9) 12 730 (10.7) 7429 (7.9) 3176 (9.7) 57 820 (21.2) 3717 (11.3)
Continued
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Characteristics
(measured 1 year (365 
days) prior to date of 
cohort drug initiation)


















 1 19 992 (21.5) 31 750 (26.8) 20 222 (21.4) 9902 (30.1) 89 693 (32.9) 9199 (27.9)
 2 27 039 (29.0) 34 897 (29.5) 27 504 (29.2) 9993 (30.4) 67 450 (24.8) 9636 (29.3)
 3 38 811 (41.6) 39 097 (33.0) 39 168 (41.5) 9797 (29.8) 57 498 (21.1) 10 390 (31.5)
Influenza shot received in 
the past year
29 985 (32.2) 36 648 (30.9) 30 500 (32.3) 9754 (29.7) 77 115 (28.3) 9779 (29.7)
Number of hospitalizations
 0 86 515 (92.8) 107 154 (90.4) 87 356 (92.6) 31 113 (94.7) 237 877 (87.3) 31 201 (94.7)
 1 5540 (5.9) 8822 (7.4) 5791 (6.1) 1507 (4.6) 27 291 (10.0) 1497 (4.5)
 2 850 (0.9) 1694 (1.4) 876 (0.9) 189 (0.6) 4858 (1.8) 183 (0.6)
 ≥3 292 (0.3) 804 (0.7) 299 (0.3) 59 (0.2) 2435 (0.9) 62 (0.2)
Number of emergency department visits
 0 74 332 (79.8) 92 328 (77.9) 74 773 (79.3) 26 767 (81.4) 203 129 (74.6) 26 847 (81.5)
 1 12 886 (13.8) 17 430 (14.7) 13 138 (13.9) 4333 (13.2) 45 534 (16.7) 4325 (13.1)
 ≥2 5979 (6.4) 8716 (7.4) 6411 (6.8) 1768 (5.4) 23 798 (8.7) 1770 (5.4)
Number of physician encounters
 0 322 (0.3) 671 (0.6) 329 (0.3) 154 (0.5) 2703 (1.0) 153 (0.5)
 1–3 6798 (7.3) 12 176 (10.3) 6747 (7.2) 3269 (9.9) 38 247 (14.0) 3263 (9.9)
 4–6 15 455 (16.6) 22 137 (18.7) 15 477 (16.4) 6250 (19.0) 51 111 (18.8) 6267 (19.0)
 ≥7 70 622 (75.8) 83 490 (70.5) 71 770 (76.1) 23 195 (70.6) 180 400 (66.2) 23 259 (70.6)
*Weighted by standardizing the comparator drug initiators to the population of SGLT2i initiators, using the propensity score odds (PS/(1−PS)), to
estimate the average treatment effect in the treated (ATT).
†The number of eligible SGLT2i initiators is different between comparisons due to the washout period exclusion used to define new use of the study 
drugs in each pairwise comparison. For the SGLT2i vs DPP4i comparison, we exclude patients who were prevalent users of either drug at baseline. 
For the SGLT2i vs non- SGLT2i comparison, we exclude patients who were prevalent users of any antidiabetic drug at baseline, which results in a 
much greater number of patients being excluded at baseline. For example, an SGLT2i initiator who receives sulfonylurea during the baseline period 
is included in the SGLT2i vs DPP4i comparison, but not in the SGLT2i vs non- SGLT2i comparison. Therefore, the SGLT2i vs DPP4i comparison 
cohort is not a strict subset of the SGLT2i vs non- SGLT2i comparison cohort. This approach is common and seeks to emulate the drug initiation 
protocol in a randomized trial.
ACEI, ACE inhibitor; COPD, chronic obstructive pulmonary disease; DPP4i, dipeptidyl peptidase-4 inhibitors; GLP, glucagon- like peptide; HbA1c, 
hemoglobin A1c; SGLT2i, sodium- glucose cotransporter-2 inhibitors; SMR, standardized mortality ratio.
Table 1 Continued
excluded all patients with baseline use of any of these 




We identified 211 671 eligible new users of SGLT2i 
(n=93 197) and DPP4i (n=118 474) and 305 329 eligible 
new users of SGLT2i (n=32 868) and non- SGLT2i antihy-
perglycemic medications (n=272 461) (table 1; see foot-
note regarding difference in SGLT2i new- user counts 
between comparisons). Crude FG IR (primary definition) 
for the SGLT2i versus DPP4i comparison was 3.8 (95% CI 
1.2 to 11.8) vs 3.2 (95% CI 1.0 to 9.9) per 100 000 person- 
years during a median follow- up of 0.58 (IQR, 0.27–1.16) 
and 0.51 (IQR, 0.25–1.05) years, respectively.
sGlT2i vs dPP4i
For all outcome definitions, the aHR of FG did not increase 
for SGLT2i initiators compared with DPP4i initiators 
(figure 1). Estimates ranged from 0.25 (95% CI 0.04 to 
1.74) to 0.76 (95% CI 0.12 to 4.97) when using ICD codes 
608.83 and N49.3 only, and 0.58 (95% CI 0.11 to 3.04) 
to 1.14 (95% CI 0.86 to 1.51) when using expanded defi-
nitions. However, CIs were wide due to the low number 
of events and there was noticeable change- in- estimate 
between crude and adjusted HR estimates (figure 1).
sGlT2i vs non-sGlT2i
We observed an increased risk of FG for SGLT2i initia-
tors compared with initiators of non- SGLT2i antihyper-
glycemic medications when using FG diagnosis codes 
only, using all diagnostic settings (aHR 1.80; 95% CI 0.53 
to 6.11) and inpatient diagnoses only (aHR 4.58; 95% 
CI 0.99 to 21.21) (figure 1). When requiring debride-
ment, surgery, or antibiotics within 7 days of diagnosis, 
we observed zero FG events in the SGLT2i cohort arm. 
Expanded diagnosis definitions yielded aHR estimates 
closer to the null, ranging from 0.66 (95% CI 0.20 to 
2.16) to 1.71 (95% CI 0.66 to 4.46).
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Figure 1 Crude and adjusted HR (aHR) estimates for Fournier’s gangrene for initiation of sodium- glucose cotransporter-2 
inhibitors (SGLT2i) compared with initiation of dipeptidyl peptidase-4 inhibitor (DPP4i) (A) and all other non- SGLT2i 
antihyperglycemic medications (B), 365- day washout period, as- treated analysis. Key to outcome definitions: Def1: Diagnosis 
list 1 (any setting)*; Def2: Diagnosis list 1 (inpatient only); Def3: Diagnosis list 2 (any setting)†; Def4: Diagnosis list 2 (inpatient 
only); Def5: Diagnosis list 3 (any setting)‡; Def6: Diagnosis list 3 (inpatient only); Def7: Diagnosis list 1 (inpatient only), plus 
either systemic antibiotics, debridement, or surgery within 7 days; Def8: Diagnosis list 1 (inpatient only), plus systemic 
antibiotics and debridement and surgery within 7 days; Def9: Diagnosis list 2 (inpatient only), plus either systemic antibiotics, 
debridement, or surgery within 7 days; Def10: Diagnosis list 2 (inpatient only), plus systemic antibiotics and debridement and 
surgery within 7 days; Def11: Diagnosis list 3 (inpatient only), plus either systemic antibiotics, debridement, or surgery within 
7 days; Def12: Diagnosis list 3 (inpatient only), plus systemic antibiotics and debridement and surgery within 7 days; Def13: 
Diagnosis list 1 (inpatient only), plus systemic antibiotics and either debridement or surgery within 7 days; Def14: Diagnosis list 
2 (inpatient only), plus systemic antibiotics and either debridement or surgery within 7 days; Def15: Diagnosis list 3 (inpatient 
only), plus systemic antibiotics and either debridement or surgery within 7 days; Def16: Diagnosis list 1 (inpatient only), plus 
either debridement or surgery within 7 days; Def17: Diagnosis list 2 (inpatient only), plus either debridement or surgery within 7 
days; Def18: Diagnosis list 3 (inpatient only), plus either debridement or surgery within 7 days. *Diagnosis list 1: 608.83, N49.3; 
†Diagnosis list 2: 608.83, N49.3, 785.4, 616.3, 616.4, N75.1, N76.4, I96; ‡Diagnosis list 3: 608.83, 608.4, N49.3, N50.1, 785.4, 
616.3, 616.4, N75.1, N76.4, I96. Outcome definitions 8, 10, and 12 yielded 0 observed outcomes and are not shown in Figure.
dIsCussIon
Using a state- of- the- art ACNU study design for real- world 
evidence, we observed an increased risk of FG for SGLT2i 
initiators compared with initiators of a broad assortment of 
non- SGLT2i antihyperglycemic medications. However, esti-
mates were imprecise due to the low number of observed 
events. These estimates appear to corroborate evidence 
behind the FDA’s initial warning, but also demonstrate 
the importance of considering the most appropriate active 
comparator when conducting comparative safety studies.
When compared with initiators of DPP4i, the most 
commonly prescribed, branded second- line antihyper-
glycemic medication class,29 SGLT2i initiation did not 
appear to be associated with an increased risk of FG. 
The DPP4i comparator reflects the clinical decision 
between prescribing two similar branded second- line 
antihyperglycemic medications, whereas the non- SGLT2i 
comparator group contains a more heterogeneous set of 
medications including first- line metformin and third- line 
insulin as well as generic medications. Our results in the 
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DPP4i comparison, which we believe to be the most rele-
vant active- comparator class of glucose- lowering drugs to 
SGLT2i, are also corroborated by a recent meta- analysis 
of randomized trials30 as well as a recent commen-
tary,12 both of which addressed the topic of FG risk and 
concluded no increased risk for SGLT2i users.
Our results also highlight the important role of outcome 
classification and confounding control decisions in the 
setting of very rare outcomes. Although our primary 
outcome definition aimed to maximize specificity, the 
precision of resulting estimates was low due to only six 
observed events from 2013 to 2017 in the DPP4i compar-
ison. This likely contributed to differences between crude 
and adjusted HR estimates; this difference decreased 
for higher- sensitivity outcome definitions. Furthermore, 
the ICD-9 diagnosis code 608.83 (‘vascular disorders, 
including Fournier’s disease’) is non- specific to FG and 
can include hematoma of the scrotum, testicles, and 
seminal vesicle. However, this is the best available ICD-9 
code and maps directly to the ICD-10 diagnosis for FG, 
N49.3, and has been used in previous studies of FG.2 4 5 
Finally, the observational design of this study precluded 
our ability to control for unmeasured confounding, 
although the ACNU study design helps to minimize the 
potential for unmeasured confounding by implicitly 
controlling for confounding by indication.13
This study fills an important evidence gap regarding FG 
risk with SGLT2i use conducted using population- level 
data. The cohort study design allows for measurement of 
incidence, which was lacking in prior FAERS analyses. The 
two- prescription exposure definition increases confidence 
that patients are actually taking study drugs compared 
with cohorts requiring just a single prescription. Finally, 
the range of outcome definitions yielded consistent 
conclusions.
ConClusIons
No evidence of increased risk of FG associated with 
SGLT2i was observed in the most relevant comparison 
with the commonly used, branded second- line antihy-
perglycemic agent, DPP4i. However, uncertainty remains 
based on potentially higher risk in the broader compar-
ison with all non- SGLT2i antihyperglycemic medications 
and the low absolute incidence of FG.
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